FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083065622> ?p ?o ?g. }

• W2083065622 endingPage "806" @default.
• W2083065622 startingPage "806" @default.
• W2083065622 abstract "Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, mental status changes, and renal dysfunction. Ticlopidine hydrochloride is 1 of several drugs that have been associated with this disorder and is currently used routinely in the approximately 500000 patients per year in the United States who undergo a percutaneous coronary intervention involving a stent.To determine the incidence and describe the clinical course of TTP due to ticlopidine therapy following stenting.Retrospective analysis of cohort of all patients undergoing coronary stenting at the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) study sites.Sixty-three centers throughout the United States and Canada.A total of 43322 patients who underwent a percutaneous coronary intervention and received a coronary stent during a 1-year period from 1996 to 1997.Cases of TTP following stenting during the 1-year period to determine the incidence of TTP due to ticlopidine therapy following coronary stenting. Additional cases were collected from these and other centers across North America to further describe the clinical presentation and course of TTP due to ticlopidine therapy following stenting.Nine cases of TTP following stenting were recognized at the 63 centers during the specified period, giving an incidence of 1 case per 4814 patients treated (0.02%; 95% confidence interval, 1 case per 2533 to 1 case per 10 541 patients treated). Ten additional cases of TTP related to ticlopidine therapy following stenting were identified from other centers, were identified from the primary centers outside the pre-defined period, or involved a noncoronary stent. Four patients (21%) received ticlopidine for 2 weeks or fewer, 14 patients (74%) for 2 to 4 weeks, and 1 patient (5%) for 8 weeks. The mean time of ticlopidine treatment prior to TTP diagnosis was 22 days (range, 5-60 days). The overall mortality rate was 21% (4/19), with all 4 deaths occurring in patients not treated with plasmapheresis, whereas there were no deaths among the 13 patients who received plasmapheresis.The findings of a TTP incidence of 0.02% in our cohort of ticlopidine-treated patients following coronary stenting suggests that TTP occurs much more commonly in this population than the estimated incidence of 0.0004% in the general population. The mortality rate for this rare complication exceeds 20%. Limiting ticlopidine therapy to 2 weeks after stenting does not prevent the development of TTP. Rapid diagnosis and treatment that includes plasmapheresis are critical for improved survival." @default.
• W2083065622 created "2016-06-24" @default.
• W2083065622 creator A5029768994 @default.
• W2083065622 creator A5046066860 @default.
• W2083065622 creator A5054364960 @default.
• W2083065622 creator A5088473438 @default.
• W2083065622 date "1999-03-03" @default.
• W2083065622 modified "2023-09-23" @default.
• W2083065622 title "Incidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary Stenting" @default.
• W2083065622 cites W1982910746 @default.
• W2083065622 cites W1993820365 @default.
• W2083065622 cites W2007516629 @default.
• W2083065622 cites W2016861625 @default.
• W2083065622 cites W2021374170 @default.
• W2083065622 cites W2026202162 @default.
• W2083065622 cites W2046336947 @default.
• W2083065622 cites W2053094051 @default.
• W2083065622 cites W2071198734 @default.
• W2083065622 cites W2083779426 @default.
• W2083065622 cites W2085652917 @default.
• W2083065622 cites W2118293115 @default.
• W2083065622 cites W2222572372 @default.
• W2083065622 cites W2315229770 @default.
• W2083065622 cites W2329490408 @default.
• W2083065622 cites W2418773538 @default.
• W2083065622 cites W2529190803 @default.
• W2083065622 cites W311320695 @default.
• W2083065622 cites W2067872984 @default.
• W2083065622 cites W3147102246 @default.
• W2083065622 doi "https://doi.org/10.1001/jama.281.9.806" @default.
• W2083065622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10071001" @default.
• W2083065622 hasPublicationYear "1999" @default.
• W2083065622 type Work @default.
• W2083065622 sameAs 2083065622 @default.
• W2083065622 citedByCount "218" @default.
• W2083065622 countsByYear W20830656222012 @default.
• W2083065622 countsByYear W20830656222013 @default.
• W2083065622 countsByYear W20830656222014 @default.
• W2083065622 countsByYear W20830656222015 @default.
• W2083065622 countsByYear W20830656222016 @default.
• W2083065622 countsByYear W20830656222017 @default.
• W2083065622 countsByYear W20830656222018 @default.
• W2083065622 countsByYear W20830656222019 @default.
• W2083065622 countsByYear W20830656222020 @default.
• W2083065622 countsByYear W20830656222022 @default.
• W2083065622 crossrefType "journal-article" @default.
• W2083065622 hasAuthorship W2083065622A5029768994 @default.
• W2083065622 hasAuthorship W2083065622A5046066860 @default.
• W2083065622 hasAuthorship W2083065622A5054364960 @default.
• W2083065622 hasAuthorship W2083065622A5088473438 @default.
• W2083065622 hasBestOaLocation W20830656221 @default.
• W2083065622 hasConcept C120665830 @default.
• W2083065622 hasConcept C121332964 @default.
• W2083065622 hasConcept C126322002 @default.
• W2083065622 hasConcept C141071460 @default.
• W2083065622 hasConcept C2777849778 @default.
• W2083065622 hasConcept C2778283817 @default.
• W2083065622 hasConcept C2778583881 @default.
• W2083065622 hasConcept C2778585876 @default.
• W2083065622 hasConcept C2778905298 @default.
• W2083065622 hasConcept C2780400711 @default.
• W2083065622 hasConcept C2780911114 @default.
• W2083065622 hasConcept C2781127562 @default.
• W2083065622 hasConcept C500558357 @default.
• W2083065622 hasConcept C61511704 @default.
• W2083065622 hasConcept C71924100 @default.
• W2083065622 hasConcept C89560881 @default.
• W2083065622 hasConceptScore W2083065622C120665830 @default.
• W2083065622 hasConceptScore W2083065622C121332964 @default.
• W2083065622 hasConceptScore W2083065622C126322002 @default.
• W2083065622 hasConceptScore W2083065622C141071460 @default.
• W2083065622 hasConceptScore W2083065622C2777849778 @default.
• W2083065622 hasConceptScore W2083065622C2778283817 @default.
• W2083065622 hasConceptScore W2083065622C2778583881 @default.
• W2083065622 hasConceptScore W2083065622C2778585876 @default.
• W2083065622 hasConceptScore W2083065622C2778905298 @default.
• W2083065622 hasConceptScore W2083065622C2780400711 @default.
• W2083065622 hasConceptScore W2083065622C2780911114 @default.
• W2083065622 hasConceptScore W2083065622C2781127562 @default.
• W2083065622 hasConceptScore W2083065622C500558357 @default.
• W2083065622 hasConceptScore W2083065622C61511704 @default.
• W2083065622 hasConceptScore W2083065622C71924100 @default.
• W2083065622 hasConceptScore W2083065622C89560881 @default.
• W2083065622 hasIssue "9" @default.
• W2083065622 hasLocation W20830656221 @default.
• W2083065622 hasLocation W20830656222 @default.
• W2083065622 hasOpenAccess W2083065622 @default.
• W2083065622 hasPrimaryLocation W20830656221 @default.
• W2083065622 hasRelatedWork W1983829728 @default.
• W2083065622 hasRelatedWork W1990829244 @default.
• W2083065622 hasRelatedWork W2025344439 @default.
• W2083065622 hasRelatedWork W2036736358 @default.
• W2083065622 hasRelatedWork W2236042039 @default.
• W2083065622 hasRelatedWork W2279896558 @default.
• W2083065622 hasRelatedWork W2328913957 @default.
• W2083065622 hasRelatedWork W2414828176 @default.
• W2083065622 hasRelatedWork W2473312721 @default.
• W2083065622 hasRelatedWork W3141478988 @default.

• next